Caseware UK (AP4) 2025.0.111 2025.0.111 2025-12-28 2025-12-28 true true No description of principal activity false 2024-12-30 false 1 1 true false 06441950 2024-12-30 2025-12-28 06441950 2024-01-01 2024-12-29 06441950 2025-12-28 06441950 2024-12-29 06441950 c:Director1 2024-12-30 2025-12-28 06441950 c:RegisteredOffice 2024-12-30 2025-12-28 06441950 c:Agent1 2024-12-30 2025-12-28 06441950 d:CurrentFinancialInstruments 2025-12-28 06441950 d:CurrentFinancialInstruments 2024-12-29 06441950 d:CurrentFinancialInstruments d:WithinOneYear 2025-12-28 06441950 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-29 06441950 d:ShareCapital 2025-12-28 06441950 d:ShareCapital 2024-12-29 06441950 d:SharePremium 2025-12-28 06441950 d:SharePremium 2024-12-29 06441950 d:RetainedEarningsAccumulatedLosses 2024-12-30 2025-12-28 06441950 d:RetainedEarningsAccumulatedLosses 2025-12-28 06441950 d:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-29 06441950 d:RetainedEarningsAccumulatedLosses 2024-12-29 06441950 d:RetainedEarningsAccumulatedLosses 2024-01-01 06441950 d:FinancialAssetsAmortisedCost 2025-12-28 06441950 d:FinancialAssetsAmortisedCost 2024-12-29 06441950 d:FinancialLiabilitiesAmortisedCost 2025-12-28 06441950 d:FinancialLiabilitiesAmortisedCost 2024-12-29 06441950 c:OrdinaryShareClass1 2024-12-30 2025-12-28 06441950 c:OrdinaryShareClass1 2025-12-28 06441950 c:OrdinaryShareClass1 2024-12-29 06441950 c:FRS102 2024-12-30 2025-12-28 06441950 c:Audited 2024-12-30 2025-12-28 06441950 c:FullAccounts 2024-12-30 2025-12-28 06441950 c:PrivateLimitedCompanyLtd 2024-12-30 2025-12-28 06441950 e:PoundSterling 2024-12-30 2025-12-28 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 06441950 ABIOMED LTD. DIRECTOR'S REPORT AND FINANCIAL STATEMENTS FOR THE PERIOD ENDED 28 DECEMBER 2025
ABIOMED LTD. COMPANY INFORMATION
Director | Paula McDonald
Registered number | 06441950
Registered office | 1 The Green
| Richmond
| Surrey
| TW9 1PL
Independent auditors | Feltons
| Chartered Accountants & Statutory Auditors
| 1 The Green
| Richmond
| Surrey
| TW9 1PL
Bankers | Barclays Bank Plc
| 29-30 High Street
| Windsor
| Berkshire
| SL4 1PG
ABIOMED LTD. CONTENTS
| Page
Director's report | 1 - 2
Independent auditors' report | 3 - 6
Statement of income and retained earnings | 7
Balance sheet | 8
Notes to the financial statements | 9 - 18
ABIOMED LTD. DIRECTOR'S REPORT FOR THE PERIOD ENDED 28 DECEMBER 2025 The director presents her report and the financial statements for the period ended 28 December 2025.
Director's responsibilities statement
The director is responsible for preparing the Director's report and the financial statements in accordance with applicable law and regulations. Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the director must not approve the financial statements unless she is satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing these financial statements, the director is required to: ∙select suitable accounting policies for the Company's financial statements and then apply them consistently; ∙make judgments and accounting estimates that are reasonable and prudent; ∙state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; ∙prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business. The director is responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable her to ensure that the financial statements comply with the Companies Act 2006. She is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Results and dividends
The loss for the period, after taxation, amounted to £15,808 (2024 - profit £1,249,622).
Director
The director who served during the period was:
Paula McDonald
Disclosure of information to auditors
The director at the time when this Director's report is approved has confirmed that: ∙so far as she is aware, there is no relevant audit information of which the Company's auditors are unaware, and ∙she has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditors are aware of that information. Page 1
ABIOMED LTD. DIRECTOR'S REPORT (CONTINUED) FOR THE PERIOD ENDED 28 DECEMBER 2025
Auditors
The auditors, Feltons, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006. This report was approved by the board and signed on its behalf.
................................................ Paula McDonald Director
Date: 5 March 2026
Page 2
ABIOMED LTD. INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF ABIOMED LTD.
Opinion
We have audited the financial statements of ABIOMED LTD. (the 'Company') for the period ended 28 December 2025, which comprise the Statement of income and retained earnings, the Balance sheet and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice). In our opinion the financial statements: ∙give a true and fair view of the state of the Company's affairs as at 28 December 2025 and of its loss for the period then ended; ∙have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and ∙have been prepared in accordance with the requirements of the Companies Act 2006.
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the director with respect to going concern are described in the relevant sections of this report. Page 3
ABIOMED LTD. INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF ABIOMED LTD. (CONTINUED)
Other information
The other information comprises the information included in the Annual Report other than the financial statements and our Auditors' report thereon. The director is responsible for the other information contained within the Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.
Opinion on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit: ∙the information given in the Director's report for the financial period for which the financial statements are prepared is consistent with the financial statements; and ∙the Director's report has been prepared in accordance with applicable legal requirements.
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Director's report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion: ∙adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or ∙the financial statements are not in agreement with the accounting records and returns; or ∙certain disclosures of director's remuneration specified by law are not made; or ∙we have not received all the information and explanations we require for our audit.
Responsibilities of directors
As explained more fully in the Director's responsibilities statement set out on page 1, the director is responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the director determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the director is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the director either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Page 4
ABIOMED LTD. INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF ABIOMED LTD. (CONTINUED)
Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below: • We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance. • We obtained an understanding of laws and regulations that could reasonably be expected to have a material effect on the financial statements through discussion with management and those charged with governance, including financial reporting and taxation legislation. We considered that extent of compliance with those laws and regulations as part of our procedures on the related financial statement items. • We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations. We remained alert to any indications of non-compliance throughout the audit. • We addressed the risk of fraud through management override by reviewing the appropriateness of a sample of journal entries and other adjustments; assessing whether the judgements made in making key accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business that we come across throughout the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the company. Our examination should not be relied upon to disclose all such material misstatements or frauds, errors or instances of non-compliance as may exist. Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation. A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' report. Page 5
ABIOMED LTD. INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF ABIOMED LTD. (CONTINUED)
Use of our report
This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed. Richard Rhodes (Senior statutory auditor) for and on behalf of Feltons Chartered Accountants Statutory Auditors 1 The Green Richmond Surrey TW9 1PL 1 April 2026 Page 6
ABIOMED LTD. STATEMENT OF INCOME AND RETAINED EARNINGS FOR THE PERIOD ENDED 28 DECEMBER 2025
| 28 December | 29 December
| 2025 | 2024
| £ | £
Turnover | 4 | 5,267,094 | 4,573,764
Cost of sales |  | (2,950,132) | (1,988,968)
Gross profit |  | 2,316,962 | 2,584,796
Administrative expenses |  | (2,053,608) | (1,308,513)
Operating profit | 5 | 263,354 | 1,276,283
Interest payable and similar expenses | 8 | (279,162) | (26,661)
(Loss)/profit before tax |  | (15,808) | 1,249,622
Tax on (loss)/profit | 9 | - | -
(Loss)/profit after tax |  | (15,808) | 1,249,622
Retained earnings at the beginning of the period |  | (1,914,204) | (3,163,826)
|  | (1,914,204) | (3,163,826)
(Loss)/profit for the period |  | (15,808) | 1,249,622
Retained earnings at the end of the period |  | (1,930,012) | (1,914,204)
The notes on pages 9 to 18 form part of these financial statements.
Page 7
ABIOMED LTD. REGISTERED NUMBER: 06441950 BALANCE SHEET AS AT 28 DECEMBER 2025
|  | 28 December |  | 29 December
|  | 2025 |  | 2024
Note |  | £ |  | £
Current assets |  |  |  |  |
Debtors: amounts falling due within one year | 10 | 2,202,999 |  | 1,552,582 |
Cash at bank and in hand | 11 | 7,786,159 |  | 2,855,727 |
|  | 9,989,158 |  | 4,408,309 |
Creditors: amounts falling due within one year | 12 | (11,919,070) |  | (6,322,413) |
Net current liabilities |  |  | (1,929,912) |  | (1,914,104)
Total assets less current liabilities |  |  | (1,929,912) |  | (1,914,104)
Net liabilities |  |  | (1,929,912) |  | (1,914,104)
Capital and reserves |  |  |  |  |
Called up share capital | 14 |  | 1 |  | 1
Share premium account |  |  | 99 |  | 99
Profit and loss account |  |  | (1,930,012) |  | (1,914,204)
|  |  | (1,929,912) |  | (1,914,104)
The financial statements were approved and authorised for issue by the board and were signed on its behalf on 5 March 2026.
................................................ Paula McDonald
Director
The notes on pages 9 to 18 form part of these financial statements. Page 8
ABIOMED LTD. NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 28 DECEMBER 2025
1. | General information
Abiomed Limited is a private limited company limited by share capital. The Company is registered in England and Wales under company number 06441950. The Company's registered office address is located at 1 The Green, Richmond Surrey TW9 1PL. The principal activity of the Company was that of the sale of heart pumps and related equipment. The current figures are for the period commencing 30th December 2024 and ending 28 December 2025, the comparatives are for the period commencing 31st December 2023 period ending 29 December 2024. The balance sheet date was changed to align the company with the reporting period of the ultimate parent company. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies (see note 3). The following principal accounting policies have been applied:
| 2.2 | Financial reporting standard 102 - reduced disclosure exemptions
The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland": ∙the requirements of Section 7 Statement of Cash Flows; ∙the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d). This information is included in the consolidated financial statements of the parent company, details of which are note 15.
| 2.3 | Going concern
The financial statements are prepared on a going concern basis. The directors of Abiomed Limited have analysed and will carry out ongoing monitoring of the impact on the company's financial position. The directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company meets its day to day working capital requirements through the support of group companies. As a result, the company continues to adopt the going concern basis of accounting in preparing the financial statements. Page 9
ABIOMED LTD. NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 28 DECEMBER 2025 2.Accounting policies (continued)
| 2.4 | Foreign currency translation
Functional and presentation currency The Company's functional and presentational currency is GBP. Transactions and balances Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined. Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges. Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of income and retained earnings within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'. Page 10
ABIOMED LTD. NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 28 DECEMBER 2025 2.Accounting policies (continued)
| 2.5 | Revenue
Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised: Sale of goods Revenue from the sale of goods is recognised on delivery when all of the following conditions are satisfied: ∙the Company has transferred the significant risks and rewards of ownership to the buyer; ∙the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold; ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the transaction; and ∙the costs incurred or to be incurred in respect of the transaction can be measured reliably. Rendering of services Revenue from a contract to provide maintenance services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied: ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the contract; ∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and ∙the costs incurred and the costs to complete the contract can be measured reliably.
| 2.6 | Finance costs
Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.
| 2.7 | Debtors
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
| 2.8 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value. Page 11
ABIOMED LTD. NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 28 DECEMBER 2025 2.Accounting policies (continued)
| 2.9 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
| 2.10 | Financial instruments
The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments. The Company has elected to apply the recognition and measurement provisions of IFRS 9 Financial Instruments (as adopted by the UK Endorsement Board) with the disclosure requirements of Sections 11 and 12 and the other presentation requirements of FRS 102. Financial instruments are recognised in the Company's Balance sheet when the Company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. Basic financial assets Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments. Other financial assets Other financial assets, which includes investments in equity instruments which are not classified as subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the recognised transaction price. Such assets are subsequently measured at fair value with the changes in fair value being recognised in the profit or loss. Where other financial assets are not publicly traded, hence their fair value cannot be measured reliably, they are measured at cost less impairment. Impairment of financial assets At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss. Financial assets are impaired when events, subsequent to their initial recognition, indicate the estimated future cash flows derived from the financial asset(s) have been adversely impacted. The Page 12
ABIOMED LTD. NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 28 DECEMBER 2025 2.Accounting policies (continued)
| 2.10 | Financial instruments (continued)
impairment loss will be the difference between the current carrying amount and the present value of the future cash flows at the asset(s) original effective interest rate. If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the profit or loss. Basic financial liabilities Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities. Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial. Debt instruments are subsequently carried at their amortised cost using the effective interest rate method. Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. Other financial instruments Derivatives, including forward exchange contracts, futures contracts and interest rate swaps, are not classified as basic financial instruments. These are initially recognised at fair value on the date the derivative contract is entered into, with costs being charged to the profit or loss. They are subsequently measured at fair value with changes in the profit or loss. Debt instruments that do not meet the conditions as set out in FRS 102 paragraph 11.9 are subsequently measured at fair value through the profit or loss. This recognition and measurement would also apply to financial instruments where the performance is evaluated on a fair value basis as with a documented risk management or investment strategy. Derecognition of financial instruments Derecognition of financial assets Financial assets are derecognised when their contractual right to future cash flow expire, or are settled, or when the Company transfers the asset and substantially all the risks and rewards of ownership to another party. If significant risks and rewards of ownership are retained after the transfer to another party, then the Company will continue to recognise the value of the portion of the risks and rewards retained. Page 13
ABIOMED LTD. NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 28 DECEMBER 2025 2.Accounting policies (continued)
| 2.10 | Financial instruments (continued)
Derecognition of financial liabilities Financial liabilities are derecognised when the Company's contractual obligations expire or are discharged or cancelled.
3. | Judgments in applying accounting policies and key sources of estimation uncertainty
The directors have applied judgment in assessing the recoverability of trade debtors and to the best of their knowledge and belief the accounts reflect a true and fair picture of the amounts of debtors the are recoverable.
4. | Turnover
The whole of the turnover is attributable to sales of heart pumps and related equipment.
| All turnover arose within the United Kingdom.
5. | Operating profit
| The operating profit is stated after charging:
|  |  |  |  | 28 December | 29 December
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Exchange differences | 20,218 | (4,028)
| During the year, no director received any emoluments (2024 - £NIL).
Page 14
ABIOMED LTD. NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 28 DECEMBER 2025
6. | Auditors' remuneration
| During the period, the Company obtained the following services from the Company's auditors and their associates:
|  |  |  |  | 28 December | 29 December
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Fees payable to the Company's auditors and their associates for the audit of the Company's financial statements | 9,450 | 7,000
| Fees payable to the Company's auditors and their associates in respect of: |  |
| All non-audit services not included above | 42,673 | 29,001
7. | Employees
| The average monthly number of employees, including the director, during the period was as follows:
|  |  | 28 December | 29 December
|  |  | 2025 | 2024
|  |  | No. | No.
|  | Directors | 1 | 1
8. | Interest payable and similar expenses
|  |  |  |  | 28 December | 29 December
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Loans from group undertakings | 279,162 | 26,661
9. | Taxation
|  |  |  |  | 28 December | 29 December
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Total current tax | - | -
Page 15
ABIOMED LTD. NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 28 DECEMBER 2025 9.Taxation (continued)
| Factors affecting tax charge for the period
| The company has significant trading losses brought forward to offset against any current taxable profits.
| Factors that may affect future tax charges
The company has significant trade losses available to carry forward against forseeable future profits. A deferred tax asset of £454,046 (2024 : £420,969) has not been recognised as its recoverability is uncertain.
10. | Debtors
|  |  |  |  | 28 December | 29 December
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Trade debtors | 1,657,121 | 1,237,156
| Amounts owed by group undertakings | 545,546 | 305,748
| Other debtors | - | 9,678
| Prepayments and accrued income | 332 | -
|  | 2,202,999 | 1,552,582
11. | Cash and cash equivalents
|  |  |  |  | 28 December | 29 December
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Cash at bank and in hand | 7,786,159 | 2,855,727
Page 16
ABIOMED LTD. NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 28 DECEMBER 2025
12. | Creditors: Amounts falling due within one year
|  |  |  |  | 28 December | 29 December
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Trade creditors | - | 3,600
| Amounts owed to group undertakings | 11,663,433 | 5,977,526
| Other taxation and social security | 96,851 | 138,479
| Other creditors | - | 33,371
| Accruals and deferred income | 158,786 | 169,437
|  | 11,919,070 | 6,322,413
13. | Financial instruments
|  |  |  |  | 28 December | 29 December
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Financial assets |  |
| Financial assets that are debt instruments measured at amortised cost | 9,989,158 | 4,408,309
| Financial liabilities |  |
| Financial liabilities measured at amortised cost | (11,761,661) | (6,034,234)
| Financial assets measured at amortised cost comprise comprise cash at bank, amounts owed by group undertakings, trade and other debtors.
| Financial liabilities measured at amortised cost comprise trade creditors, other creditors, accruals and amounts owed to group undertakings.
Page 17
ABIOMED LTD. NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 28 DECEMBER 2025
14. | Share capital
|  |  |  |  | 28 December | 29 December
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
|  | Allotted, called up and fully paid |  |
|  | 1 (2024 - 1) Ordinary share of £1.00 | 1 | 1
15. | Controlling party
Abiomed Limited considers Abiomed R&D Inc to be its immediate parent company. The ultimate controlling party is Johnson & Johnson. Both Abiomed R&D Inc and Johnson & Johnson are companies in the United States of America. The principle executive offices of the group headed by Abiomed Inc are located at 22 Cherry Hill Drive, Danvers, Massachusetts, 01923. The website address of Abiomed Inc is www.abiomed.com. The Group Financial Statements are made available free of charge through the investors section of the website.
Page 18